ZS/DC S015 dendritic cell vaccine - Zhongsheng Kangyuan Biotechnology
Alternative Names: ZS/DC-S015 dendritic cell vaccine - Zhongsheng Kangyuan BiotechnologyLatest Information Update: 04 Aug 2021
At a glance
- Originator Zhongsheng Kangyuan Biotechnology
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cholangiocarcinoma
Most Recent Events
- 23 Jul 2021 Early research in Cholangiocarcinoma in China (IV) as at July 2021 (Zhongsheng Kangyuan Biotechnology pipeline; July 2021)
- 01 Jun 2020 Zhongsheng Kangyuan Biotechnology plans a phase 0 trial for Cholangiocarcinoma in China in mid 2020 (Zhongsheng Kangyuan Biotechnology pipeline; July 2021)